Cambridge, UK and Boston, Massachusetts-based CellCentric has appointed Celia Economides as chief financial officer and chief business officer.

She will oversee financial strategy, business development and investor relations.

Economides has more than two decades of strategic leadership experience across biotech finance, corporate development and capital markets. She previously held senior roles at several publicly traded biotechnology companies and was most recently interim chief executive and chief financial officer of Gritstone bio.

Will West, chief executive of CellCentric, said: “[Economides’] proven leadership in building and financing biotech companies, coupled with her deep understanding of the US market will be instrumental as we advance [CellCentric’s novel oral p300/CBP inhibitor] inobrodib towards registration. Our global footprint is expanding rapidly to meet the needs of our next phase of progress, with the goal of improving the lives of people with multiple myeloma.”

Economides commented: “I am honoured to join CellCentric at such an exciting inflection point. Inobrodib is truly a compelling potential oral first-in-class treatment for multiple myeloma. I look forward to partnering with Will, the board, our investors, and the CellCentric team to shape the next phase of growth, maximise value and ultimately bring a much-needed treatment to patients.”

Earlier this month CellCentric announced a $120 million Series C financing co-led by RA Capital Management and Forbion.